A UCLA group and spinout FetoLumina Technologies are working on a clinical assay for noninvasive prenatal diagnostics.
At a conference last week, researchers from Italy presented results from 73 women who had mosaic embryos transferred.
Premaitha will issue Thermo Fisher warrants over 28,938,797 new ordinary shares and a second tranche of warrants in 2018.
Counsyl believes its data is robust, while Natera has called the methodology and conclusions "gratuitously wrong." Both published opposing response letters this week.
According to John Zhang, founder and CEO of the New Hope Fertility Center, universal PGS will likely increase success rates of IVF further.
A study by researchers in Italy found that preimplantation genetic diagnosis and screening combined led to more successful pregnancies per transfer but fewer women had embryos transferred.
At last week's ESHG annual meeting, three quality assessment providers discussed best practice guidelines and results from a pilot NIPT quality assessment scheme.
In a report made public this week, the French National Authority for Health recommended NIPT if first semester screening indicated a risk between 1 in 51 and 1 in 1,000.
For the year ended March 31, the Manchester, UK-based provider of noninvasive prenatal testing reported more than £3.1 million ($4 million) in revenue.
The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.